SCHEMBL2353600

SCHEMBL2353600

NC(=O)c1[nH]c2ccc(Cl)cc2c1S(=O)(=O)NCc1cccc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.52
TP53 P04637 1/20 0.48
MAP2 P11137 8/20 0.47
PTPN1 P18031 1/20 0.47
PTPN6 P29350 1/20 0.47
PTPN11 Q06124 1/20 0.47
MCL1 Q07820 1/20 0.45
CYP19A1 P11511 1/20 0.44
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
TUBA1B P68363 1/20 0.43
TUBA4A P68366 1/20 0.43
TUBB4B P68371 1/20 0.43
TUBB3 Q13509 1/20 0.43
TUBB2A Q13885 1/20 0.43
TUBB8 Q3ZCM7 1/20 0.43
TUBA3E Q6PEY2 1/20 0.43
TUBA1A Q71U36 1/20 0.43
TUBA1C Q9BQE3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2344495 0.92 MAP2 (0.54) CNR1MAP2KDM4EALDH1A1SIRT2
SCHEMBL2349489 0.90 MAP2 (0.52) CNR1TP53MAP2PTPN1PTPN6
SCHEMBL2349576 0.89 LMNA (0.45) CNR1MAP2CYP19A1
SCHEMBL2341743 0.84 CNR1 (0.53) CNR1TP53MAP2KDM4EALDH1A1
SCHEMBL2346188 0.84 MAP2 (0.49) CNR1MAP2PTPN1PTPN6PTPN11
SCHEMBL2341414 0.83 MAP2 (0.51) CNR1MAP2TUBB4ATUBBTUBA3C
SCHEMBL2344487 0.82 MAP2 (0.50) CNR1TP53MAP2KDM4EALDH1A1
SCHEMBL2350074 0.82 MAP2 (0.50) MAP2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2344739 0.81 MAP2 (0.49) CNR1MAP2TUBB4ATUBBTUBA3C
SCHEMBL2351779 0.81 MAP2 (0.50) TP53MAP2TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008295-B2 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2011-08-30 US claimed
US-20100041652-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-02-18 US claimed
US-20080008708-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1534268-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2006-11-02 EP claimed
US-20060128783-A1 Tyrosine kinase inhibitors DINSMORE CHRISTOPHER J 2006-06-15 US claimed
EP-1534268-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2005-06-01 EP claimed
WO-2004014300-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2004-02-19 WO claimed
US-8008295-B2 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2011-08-30 US disclosed
US-20100041652-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-02-18 US disclosed
US-20080008708-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20060128783-A1 Tyrosine kinase inhibitors DINSMORE CHRISTOPHER J 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128783-A1 Tyrosine kinase inhibitors ABL1, ERBB2, JAK2 CNR1 344/4885TP53 609/4885MAP2 721/4885
US-20080008708-A1 Tyrosine kinase inhibitors ABL1, ERBB2, JAK2 CNR1 344/4885TP53 609/4885MAP2 721/4885
US-20100041652-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, JAK2 CNR1 344/4885TP53 609/4885MAP2 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.